Categories

CEO Mark Capone describes the unique Myriad culture and what the “DNA of a Myriadian” means to us. “We recognize that every single thing we do every day, there’s a patient at the other end of our work and that what we do matters to that patient.”

Continue Reading

CEO Mark Capone looks at the pioneering role Myriad is playing a as we enter the golden era of molecular diagnostics and what he envisions for our future. “In the next five years, there will be incredible discoveries and we are going to transform the lives of our patients around the world in ways that…

Continue Reading

CEO Mark Capone talks about our mission, which is to answer patients’ four most pressing questions in six medical specialties.

Continue Reading


CEO Mark Capone describes the Myriad Vision and what it means to us. “We want to be the trusted advisor transforming patients lives with our pioneering molecular diagnostics.”

Continue Reading

Myriadians are passionate about saving and improving the lives of patients worldwide with our breakthrough molecular diagnostic tests. That commitment extends beyond the office and is why so many of our employees actively give back to their communities. Each October, we participate in the American Cancer Society’s Making Strides Against Breast Cancer Walk , which…

Continue Reading

CEO Mark Capone talks about why patients and physicians choose Myriad when decisions matter most. “We recognize that patients are going to use the information we provide and it will transform their lives in incredible ways. Therefore, it is our responsibility to make sure that that information is correct.”

Continue Reading

Myriad has changed a lot over the past 20 years. We’ve gone from being a single product company in just the United States to a company with 15 products on the market or in development and operations around the world. We are transforming into a leader in the personalized medicine industry with our innovative, high-quality…

Continue Reading

At Myriad, corporate responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives. Our corporate social responsibility programs are designed to: · Build greater value for our patients, healthcare professionals and shareholders; · Support and improve the communities where we live…

Continue Reading

On August 13, 2015, Medicare approved coverage of the Prolaris® test for men diagnosed with low-risk and very low-risk prostate cancer. The decision is the culmination of years of scientific discovery, research and collaboration, and is an enormous step in improving patient care. Every day, 630 men in the United States are diagnosed with prostate…

Continue Reading